Esophageal Cancer Management: Preoperative CA19.9 and CEA Serum Levels May Identify Occult Advanced Adenocarcinoma
- 310 Downloads
Esophagectomy is contraindicated in case of advanced cancer (i.e., carcinomatosis, distant metastasis, and invasion of other organs). In some cases, preoperative imaging may fail to identify advanced neoplasm and esophagectomy is inappropriately planned. The aim of the study was to identify preoperative biomarkers of occult advanced disease that force surgeons to abort the planned esophagectomy.
From 2008 to 2014, 244 consecutive patients were taken to the operative room to have esophagectomy for cancer in our department. All of them had blood test at admission and their preoperative biomarker data were retrieved. Their medical history was collected and the intraoperative findings and outcome were recorded. Non parametric tests, multiple regression analysis, and ROC curves analysis were performed.
In our study group, 14 (5.7 %) patients, scheduled for esophagectomy, were discovered to have occult advanced disease at laparotomy/laparoscopy or at thoracotomy. Six of them had peritoneal carcinomatosis, three had advanced tumor invading other organs, three had small liver metastasis, and two pleural carcinomatosis. In all these cases, esophagectomy was aborted and a feeding jejunostomy was placed. In patients with unresectable esophageal cancer, CA19.9 and CEA serum levels were significantly higher than patients who could have esophagectomy (p < 0.001 and p = 0.003, respectively). CA19.9 and CEA resulted to be accurate biomarkers of occult advanced disease (AUC = 85 %, p < 0.001 and AUC = 73 %, p = 0.002, respectively).
Preoperative CEA and CA19.9 serum levels should be taken in consideration when evaluating patients candidate to esophagectomy for esophageal cancer to prevent inappropriate laparotomy or thoracotomy. If any doubt arises minimally invasive exploration is warranted.
KeywordsPancreatic Cancer Esophageal Cancer Esophageal Squamous Cell Carcinoma Peritoneal Carcinomatosis Esophageal Adenocarcinoma
- 7.Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW (2010) Outcomes of patients with esophageal cancer staged with [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 28(31):4714–4721. doi: 10.1200/JCO.2010.30.7702 PubMedCentralPubMedCrossRefGoogle Scholar
- 8.Thomas SN, Zhu F, Schnaar RL, Alves CS, Konstantopoulos K (2008) Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. J Biol Chem 283(23):15647–15655. doi: 10.1074/jbc.M800543200 PubMedCentralPubMedCrossRefGoogle Scholar
- 10.Duffy MJ, Van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O (2003) Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 39(6):718–727. doi: 10.1016/S0959-8049(02)00811-0 PubMedCrossRefGoogle Scholar
- 14.Sobin L, Wittekind C, UICC (2002) TNM classification of malignant tumors, 6th edn. Wiley, New YorkGoogle Scholar
- 26.Kim YC, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Shin JH (2009) Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol 24(12):1869–1875. doi: 10.1111/j.1440-1746.2009.05935.x PubMedCrossRefGoogle Scholar
- 27.Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K (2007) Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 14(6):539–544PubMedCrossRefGoogle Scholar